Amgen Inc.
AMGN · Nasdaq
- $377.35
- $206.25B
- Open
- —
- —
- $0.00 - $0.00
- $269.77 - $447.03
- —
- —
- 2.71M
About Amgen Inc.
Amgen is a biotechnology company that discovers, develops, manufactures and sells prescription medicines, with products aimed at serious diseases across areas including oncology and other specialty-care markets. It makes money primarily by selling biologic and other therapies through healthcare providers, pharmacies, hospitals and government and commercial insurers to patients worldwide. The company reported $36.8 billion of FY2025 revenue and $7.7 billion of net income, compared with $33.4 billion and $4.1 billion in FY2024. The supplied evidence does not provide revenue contributions by therapeutic segment. Amgen’s scale is therefore best reflected by its multibillion-dollar global revenue base and established commercial infrastructure.
Notable Price Movement
- Sep 7-11$377.3513.70%
Amgen fell $36.71, or 8.54%, from $429.88 to $393.17 over the week, with the decline concentrated in the final session. The stock initially rose from $429.88 on August 31 to $444.12 on September 3, gaining as investors focused on positive oncology data, including a reported Phase 3 survival benefit for an Amgen-AstraZeneca combination in lung cancer. It then reversed modestly to $437.23 on September 4 before plunging to $393.17 on September 8 on heavy volume of 6.83 million shares. Coverage attributed the selloff to a trial setback involving a study Amgen did not run, alongside broader concern about the company’s oncology outlook. The move sharply underperformed the broader Nasdaq, which was supported by chip stocks.
- Aug 31 - Sep 4$437.231.11%
Amgen rose 1.63% over the period, from $436.99 to $444.12, after initially weakening to $429.88 on Monday. The stock then reversed higher, gaining 1.9% Tuesday and continuing to advance through Thursday, when it closed at a new period high. The most concrete company-specific support was Wells Fargo’s decision to maintain its rating while raising its price target to $435 on the drug-trial outlook. Coverage also highlighted higher 2026 guidance, TEZSPIRE data and the potential of MariTide in obesity treatment. The move occurred without a material reversal after Tuesday’s rebound, although the stock first gave back the prior week’s losses before recovering them.
- Aug 24-28$432.421.57%
Amgen fell $6.91, or 1.57%, from $439.33 to $432.42 over the week. The stock initially gained $4.51 on Monday to $443.84, then declined on each of the next four sessions, including a $3.35 drop Thursday and a further $4.57 Friday. The most concrete company-specific development was Thursday’s announcement that AstraZeneca and Amgen’s Phase 3 CROSSING trial of Tezspire met its co-primary and key secondary endpoints in eosinophilic esophagitis, a positive result supporting potential expansion. That news did not prevent the late-week reversal, and the supplied evidence does not identify a specific reason for the subsequent selling. Articles also discussed Amgen’s exit from TScan’s Crohn’s deal and valuation, patent-loss and pricing risks.
- Aug 10-14$415.211.04%
AMGN rose 10.12%, from $378.87 to $417.20, extending gains on four of the five sessions shown. The stock climbed 2.9% on Aug. 4 and another 4.6% on Aug. 5, then gave back 0.7% on Aug. 6 before recovering 1.5% on Aug. 7 and 1.5% on Aug. 10. Trading volume peaked at 5.75 million shares on Aug. 5, materially above the surrounding sessions. The supplied evidence does not identify a definitive company-specific catalyst or broader-market explanation. Barclays maintained its rating while raising its price target to $380, and coverage highlighted strong GLP-1 demand, but neither item fully explains the move, particularly with the shares finishing above that target.
- Aug 3-7$410.956.69%
Amgen fell $3.08, or 0.78%, from $393.10 on July 28 to $390.02 on August 4. The stock dropped $5.46 on July 29, was unchanged July 30, and fell another $2.48 July 31 before reversing sharply with an $11.15 gain on August 4. The rebound followed second-quarter results showing improved profit and revenue growth, earnings and revenue beats of 12.32% and 6.52%, respectively, 37% growth in Repatha sales, and higher 2026 earnings guidance. Thus, the week reflected a material pre-earnings decline followed by a strong earnings-day recovery, but the rebound did not fully erase the earlier losses.
